How has NewAmsterdam Pharma Company's net investment in lease changed year-over-year?

NewAmsterdam Pharma Company's net investment in lease decreased by 94.3% year-over-year, from $369K to $21K.

What is the long-term trend for NewAmsterdam Pharma Company's net investment in lease?

Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's net investment in lease has grown at a 15.5% compound annual growth rate (CAGR), from $120K to $185K.

NewAmsterdam Pharma Company NAMS Net Investment in Lease

Net Investment in Lease at other companies

Denali Therapeutics Inc.DNLI

——

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's net investment in lease?: NewAmsterdam Pharma Company (NAMS) reported net investment in lease of $21K in Q1 2026.
How has NewAmsterdam Pharma Company's net investment in lease changed year-over-year?: NewAmsterdam Pharma Company's net investment in lease decreased by 94.3% year-over-year, from $369K to $21K.
What is the long-term trend for NewAmsterdam Pharma Company's net investment in lease?: Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's net investment in lease has grown at a 15.5% compound annual growth rate (CAGR), from $120K to $185K.